Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
13.50
+0.15 (1.12%)
Dec 20, 2024, 4:00 PM EST - Market closed
Contineum Therapeutics Revenue
In the year 2023, Contineum Therapeutics had annual revenue of $50.00M.
Revenue (ttm)
$50.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
$1,612,903
Employees
31
Market Cap
348.00M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 50.00M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCTNM News
- 5 days ago - Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 - Business Wire
- 27 days ago - Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference - Business Wire
- 4 weeks ago - Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain - Business Wire
- 5 weeks ago - Contineum Therapeutics to Attend Upcoming Investor Conferences - Business Wire
- 6 weeks ago - Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Business Wire
- 4 months ago - Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences - Business Wire
- 4 months ago - Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Business Wire
- 5 months ago - Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis - Business Wire